Bristol-Myers Squibb Shares Outstanding 2006-2018 | BMY

Current and historical number of shares outstanding for Bristol-Myers Squibb (BMY) from 2006 to 2018. Diluted shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options.
Bristol-Myers Squibb Annual Shares Outstanding
(Millions of US $)
2017 $1,652
2016 $1,680
2015 $1,679
2014 $1,670
2013 $1,662
2012 $1,688
2011 $1,717
2010 $1,727
2009 $1,978
2008 $1,999
2007 $1,977
2006 $1,963
2005 $1,983
Bristol-Myers Squibb Quarterly Shares Outstanding
(Millions of US $)
Q2 2018 $1,636
Q1 2018 $1,640
Q4 2017 $1,652
Q3 2017 $1,645
Q2 2017 $1,650
Q1 2017 $1,671
Q4 2016 $1,680
Q3 2016 $1,679
Q2 2016 $1,679
Q1 2016 $1,680
Q4 2015 $1,679
Q3 2015 $1,678
Q2 2015 $1,667
Q1 2015 $1,676
Q4 2014 $1,670
Q3 2014 $1,670
Q2 2014 $1,669
Q1 2014 $1,666
Q4 2013 $1,662
Q3 2013 $1,662
Q2 2013 $1,660
Q1 2013 $1,655
Q4 2012 $1,688
Q3 2012 $1,666
Q2 2012 $1,701
Q1 2012 $1,706
Q4 2011 $1,717
Q3 2011 $1,715
Q2 2011 $1,722
Q1 2011 $1,714
Q4 2010 $1,727
Q3 2010 $1,726
Q2 2010 $1,728
Q1 2010 $1,725
Q4 2009 $1,978
Q3 2009 $1,984
Q2 2009 $1,983
Q1 2009 $1,981
Q4 2008 $1,999
Q3 2008 $2,002
Q2 2008 $2,006
Q1 2008 $2,008
Q4 2007 $1,977
Q3 2007 $2,012
Q2 2007 $2,006
Q1 2007 $1,997
Q4 2006 $1,963
Q3 2006 $1,992
Q2 2006 $1,994
Q1 2006 $1,988
Q4 2005 $1,983
Q3 2005 $1,984
Q2 2005 $1,984
Q1 2005 $1,981
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $96.944B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $350.789B 16.76
Pfizer (PFE) United States $243.651B 14.26
Novartis AG (NVS) Switzerland $190.263B 16.32
Merck (MRK) United States $178.137B 15.73
AbbVie (ABBV) United States $145.067B 14.17
Novo Nordisk (NVO) Denmark $114.528B 18.31
Eli Lilly (LLY) United States $109.815B 20.33
Sanofi (SNY) France $104.261B 13.20
AstraZeneca (AZN) United Kingdom $99.745B 10.97
GlaxoSmithKline (GSK) United Kingdom $99.569B 13.30